About Quark Venture
Quark Venture is a venture capital firm founded in 2016. It is primarily based out of Vancouver, Canada. As of Dec 2022, Quark Venture has invested in 30 companies. It primarily invests in Series B round in United States based startups. Its investments are spread across a wide range of sectors from Life Sciences to HealthTech and High Tech. Most recently it participated in the $***** Series B round of Alpha-9 Oncology Overall, Quark Venture portfolio has seen 3 IPOs and 6 acquisitions including key companies like Keros Therapeutics, CalciMedica and CathWorks. A lot of funds co-invest with Quark Venture, with names like GF Securities sharing a substantial percentage of its portfolio. Quark Venture has team of 2 people including 2 partners.Key Metrics
Team Members
Portfolio Count
Portfolio Sectors
Portfolio Locations
Rounds of Entry
Series B, Series C & 2 more
Portfolio IPOs
Portfolio Soonicorns
Quark Venture's List of Top Investments
Quark Venture has a portfolio of 30 companies. Their most notable investments are in SQZBiotech and Bioarray.Their portfolio spans across United States, Israel, Canada and 3 more locations. They have invested in Life Sciences, HealthTech, High Tech and 4 other sectors, across stages such as Series B, Series C and 2 more. Here is the list of top investments by Quark Venture:
Keros Therapeutics is developing small molecules and biologics for rare neuromuscular and hematologic diseases. The product pipeline involves KER-050 to treat myelodysplastic syndrome and myelofibrosis (phase II); KER-047 to treat hepcidin-cased anemia and fibrodysplasia ossificans progressive (FOP); KER-012 to treat pulmonary arterial hypertension and bone disorders.
Key facts about Keros Therapeutics
- Founded Year: 2016
- Location: Lexington (United States)
- Annual Revenue: $100M - $500M as on Dec 31, 2025
- Stage: Public
- Total Funding till date: $90M
- Employee Count: 122 as on Aug 31, 2026
- Investors: Foresite Capital, Pontifax and 9 Others
- Latest Funding Round: Series C, Mar 04, 2020, $*****
- Highlight: Public
2. CalciMedica
Developer of CRAC channel inhibitor drugs for inflammatory diseases. The Company has a portfolio of highly selective CRAC channel inhibitor drugs that it is developing to improve outcomes for patients with acute inflammatory indications.
Key facts about CalciMedica
- Founded Year: 2006
- Location: San Diego (United States)
- Stage: Public
- Total Funding till date: $76.7M
- Employee Count: 18 as on Aug 31, 2026
- Investors: Aisling Capital, Bering Capital and 11 Others
- Latest Funding Round: Venture Debt, Apr 06, 2025, $*****
- Highlight: Public
3. CathWorks
CathWorks is developing FFRAngio, a novel technology for angiogram-based physiology measurement that does not require pressure wires or hyperemic stimulus. It is based on the processing of visual information and automatic multi-layered algorithms. Its technology is focused on improving the utilization of coronary angiography data to validate measurement-based medicine in the cath lab.
Key facts about CathWorks
Eloxx Pharmaceuticals is a developer of small molecule drugs for genetic diseases caused by nonsense mutations. It helps in treating genetic diseases caused by nonsense mutations including Cystic fibrosis, Duchene Muscular Dystrophy, Usher syndrome, Ataxia-telangiectasia, Beta-thalassemia and Tay-Sachs Hurler syndrome. Based on the technology developed at Israel Institute of technology, it is building a pipeline of molecules that can induce ribosomal readthrough to overcome the nonsense mutations and allow production of a full-length functional protein and hold great therapeutic potential for the treatment of many genetic diseases.
Key facts about Eloxx Pharmaceuticals
- Founded Year: 2013
- Location: Herzliya (Israel)
- Annual Revenue: $1M - $10M as on Dec 31, 2024
- Stage: Public
- Total Funding till date: $38M
- Employee Count: 12 as on Aug 31, 2026
- Investors: Advent Life Sciences, Life Sciences Partners and 15 Others
- Latest Funding Round: Grant (prize money), Mar 29, 2022, $*****
- Highlight: Public
5. EyeYon
Developer of ophthalmic devices for the treatment of corneal edema. The Hyper-CL™ therapeutic contact lens for the treatment of corneal pathologies. Another product EndoArt is a polymer film implant that is attached to the posterior corneal surface to treat corneal edema secondary to endothelial dysfunction.
Key facts about EyeYon
- Founded Year: 2011
- Location: Ness Ziona (Israel)
- Stage: Series C
- Total Funding till date: $36M
- Employee Count: 28 as on Aug 31, 2026
- Investors: Pontifax, Triventures and 10 Others
- Latest Funding Round: Series C, Mar 15, 2021, $*****
- Highlight: Editors' Pick
Quark Venture's Year-on-Year Investment Trends
Quark Venture has invested in 30 companies over the last 10 years, with an average of 2 new investments annually in the last 10 years. Its most recent first time investment was in Alpha-9 Oncology and most recent follow-on round was in Lyndra.Year | No. of Investments | ||
|---|---|---|---|
1st Round | Follow-on | Total | |
2026 (YTD) | 0 | 0 | 0 |
2025 | 0 | 0 | 0 |
2024 | 0 | 0 | 0 |
2023 | 0 | 0 | 0 |
2022 | 2 | 0 | 2 |
2021 | 3 | 1 | 4 |
2020 | 2 | 2 | 4 |
2019 | 3 | 1 | 4 |
2018 | 2 | 1 | 3 |
2017 | 10 | 3 | 13 |
Quark Venture's Investments by Stage
Quark Venture has made 13 investments in Series B stage with an average round size of $26.6M, 5 investments in Series C stage with an average round size of $33.4M, 4 investments in Series A stage with an average round size of $19.5M and 3 investments in Seed stage with an average round size of $3.27M.Stage of entry | No. of Investments |
|---|---|
Series B | 13 |
Series C | 5 |
Series A | 4 |
Seed | 3 |
Note: We have considered here, only first round of investments
Quark Venture's Investments by Sector
Quark Venture has a diverse portfolio, with companies operating in the Life Sciences, High Tech, Enterprise Applications, HealthTech and Big Data - Industry Applications. Notably, it has invested in 28 Tech companies, 26 Enterprise (B2B) companies, 5 Software companies and at least 3 companies focusing on Tech hardware.Sector | No. of Investments |
|---|---|
Life Sciences | 21 |
High Tech | 4 |
Enterprise Applications | 3 |
HealthTech | 3 |
Big Data - Industry Applications | 1 |
Others | 4 |
Note: We have considered here, only first round of investments
Quark Venture's Investments by Geography
Quark Venture has made most investments in United States (11), followed by Canada where it has made 6 investments.Country | No. of Investments |
|---|---|
United States | 11 |
Canada | 6 |
Israel | 6 |
China | 1 |
France | 1 |
Note: We have considered here, only first round of investments
Quark Venture's recent investments
Quark Venture has not made any investment in 2026 so far.Here are the most recent investments by Quark Venture:
Filter this listDate | Company | Location | Round Details | Round Amount | Co-Investors |
|---|---|---|---|---|---|
Dec 14, 2022 | United States | Series B | 4521 | [+4] | |
Dec 14, 2022 | Canada | Series B | 7670 | [+4] | |
Jun 24, 2021 | United States | Series C | 4325 | [+7] | |
Apr 06, 2021 | United States | Seed | 2713 | [+4] | |
Mar 15, 2021 | Israel | Series C | 2681 | [+5] |
IPOs and Publicly Listed companies in Quark Venture's Portfolio
3 of Quark Venture's portfolio companies have become public. CalciMedica got listed on the National Association of Securities Dealers Automated Quotations (NASDAQ), in Sep 2020 and Keros Therapeutics got listed on the National Association of Securities Dealers Automated Quotations (NASDAQ) at marketcap of $307M.Here are Quark Venture's portfolio companies that went public:
Company | IPO Date | First Invested on | First Round of Investment | Round Size |
|---|---|---|---|---|
Sep 25, 2020 | - | - | 8187 | |
Apr 08, 2020 | Jan 07, 2019 | Series B | 2663 | |
Feb 26, 2016 | Jun 08, 2017 | Series C | 2880 |
Acquired companies in Quark Venture's Portfolio
6 companies from Quark Venture's portfolio have been acquired. The most recent acquisition was CathWorks in Apr 2026 by Medtronic for $*****.Here are Quark Venture's portfolio companies that got acquired most recently:
Company | Acquisition Date | First Invested on | First Round of Investment | Round Size |
|---|---|---|---|---|
Apr 20, 2026 | Oct 02, 2017 | Series B | 6302 | |
Aug 20, 2024 | 2017 | Series C | 5531 | |
Mar 05, 2024 | 2017 | Seed | 8144 | |
Feb 29, 2024 | Dec 01, 2016 | Series B | 8543 | |
Nov 20, 2019 | - | - | 3064 |
Team profile of Quark Venture
Quark Venture has a team of 2 members including 2 Partners located in United States and Canada. Quark Venture's team sits on the board of 1 company.Co-investors of Quark Venture
Over the past 10 years, 178 investors have co-invested in Quark Venture's portfolio companies. This includes funds and angels.
- Invested before Quark Venture: Pontifax, Triventures and 52 others have invested in rounds before Quark Venture. There are 4 companies where Pontifax has invested before Quark Venture and 2 companies where Triventures has invested before Quark Venture.
- Top Co-investors of Quark Venture: 53 investors entered a company along with Quark Venture. These include investors like GF Securities (13 companies).
- Invested after Quark Venture: A total of 71 investors have invested in Quark Venture's portfolio after their investments. Top Investors include Deerfield (2 companies), Korea Investment Holdings (2 companies) and Invus (2 companies).
Recent News related to Quark Venture
•
Targeted radiotherapy biotech out of Longitude Capital raises a fresh $75MEndPoints News•Dec 14, 2022•Alpha-9 Theranostics, Longitude Capital, Nextech Invest, Frazier Healthcare Partners and 2 others
•
Lyndra Therapeutics Closes $60.5M Series C FinancingFinSMEs•Jun 27, 2021•Lyndra, AIG, Yipinhong pharmaceutical, Limitlessventures and 6 others
•
Volastra Therapeutics Expands Seed Funding to $44MFinSMEs•Apr 06, 2021•Volastra, Vida Ventures, Catalio Capital Management, Polaris Partners and 3 others
•
Biotech startup Variantyx raises $20M in funding for whole-genome sequencing method to treat rare diseasesTechStartups.com•Mar 15, 2021•Variantyx, Quark Venture, GF Securities, IBM and 3 others
•
Israeli startup EyeYon Medical completes $25M Series C roundMobiHealthNews•Mar 15, 2021•EyeYon, Triventures, Rimonci, Pontifax and 7 others
•
Finnov to clean out China backers, eyes new investors Premji, Mirae, othersVCCircle•Oct 27, 2020•Finnov, Lexin Capital, Shunwei Capital, Alpine Investors and 2 others
•
Medical Device Maker Gets $98 MillionSan Fernando Valley Business Journal•Sep 23, 2020•V-Wave, Deerfield, Aperture Venture Partners, BRM and 8 others
•
Artms Closes US$19M Series A FinancingFinSMEs•May 20, 2020•ARTMS, Deerfield, Quark Venture, GF Securities
•
EnClear Therapies Announces $10M Series A FinancingBusiness Wire•Feb 19, 2020•20/20 HealthCare Partners, EnClear Therapies, Amgen Business Development, Dolby Family Ventures and 3 others
•
Volastra Therapeutics Raises $12M in Seed FinancingFinSMEs•Feb 11, 2020•Volastra, Polaris Partners, Droia, Quark Venture and 2 others
